Single bolus doses of Angiomax up to 7.5 mg/kg have been reported without associated bleeding or other adverse events. Discontinuation of Angiomax leads to a gradual reduction in anticoagulant effects due to metabolism of the drug. In cases of overdosage, treatment with Angiomax should be immediately discontinued and the patient monitored closely for signs of bleeding. Angiomax is hemodialyzable (see CLINICAL PHARMACOLOGY, Pharmacokinetics). There is no known antidote to Angiomax.

Angiomax is contraindicated in patients with:

-     active major bleeding;

-     hypersensitivity to Angiomax or its components.

Bookmark this page: